PRP May Offer the Strongest Hair Transplant Evidence - Summary - MDSpire
Advertisement
PRP May Offer the Strongest Hair Transplant Evidence
Structured review highlights stronger evidence for platelet-rich plasma than for exosome-based and other emerging regenerative therapies while underscoring the need for standardized transplantation-specific research.
To evaluate the effectiveness of regenerative therapies for hair loss and hair transplantation, focusing on platelet-rich plasma (PRP) and other emerging approaches.
Approach:
Study Design: Structured narrative review of English-language studies from PubMed/MEDLINE, Scopus, and Google Scholar through February 2025.
Eligibility Criteria: Included randomized controlled trials, prospective and retrospective clinical studies, systematic reviews, meta-analyses, and translational preclinical studies.
Outcome Measures: Assessed hair density, hair shaft diameter, graft survival, hair yield, wound healing, time to visible regrowth, shock loss, and patient-reported satisfaction.
Key Findings:
PRP had the most mature evidence base among reviewed therapies.
Randomized trials reported increases in hair density of approximately 10 to 30 hairs/cm² with PRP.
Evidence specific to hair transplantation was limited and inconsistent.
Exosome-based therapies had considerably less developed evidence, with no robust randomized trials.
Low-level laser therapy showed moderate evidence for androgenetic alopecia, but transplantation-specific data was limited.
Interpretation:
PRP is currently the best-supported regenerative adjunct in hair transplantation, but higher-quality studies are needed for broader clinical application.
Limitations:
Narrative design limited quantitative synthesis.
Potential selection bias and heterogeneity in included literature.
Variability in treatment protocols and outcome reporting.
Conclusion:
Standardized protocols and transplantation-specific outcome measures are essential for improving future evidence quality.
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.
